Metrics Contract Services Invests in Leading Liquid Chromatography Technologies
Metrics has acquired two new Waters ACQUITY Ultra Performance Liquid Chromatography H-class (UPLC) systems. These additional UPLC systems will help the company’s chemists produce better resolution liquid-chromatography separations in shorter analysis times, thus improving characterization of complex samples.
“Our clients have been requesting our help with exactly these types of analytical projects, so it’s exciting to expand our capabilities in support of our customers’ programs,” said Jennifer Alligood, Associate Director of Analytical Services.
This equipment acquisition is the latest in a series of investments Metrics has been making in its physical facilities and equipment. Most recently, the company added a Thermo Scientific iCAP Q ICP-MS mass spectrometer and a Milestone UltraWAVE Single Reaction Chamber digestion vessel.
“Metrics’ ongoing investment in leading-edge laboratory technologies reflects our commitment to providing clients with scientific excellence – in terms of providing quality data and fast turnaround times, as well as thoughtful interpretation of what those results mean for them,” Ms. Alligood added.
Metrics has long appreciated the importance of analytical support within the context of pharmaceutical development and manufacturing. Today, Metrics has more than 90 analytical chemists on staff – which represents an industry-leading four analytical chemists for every one of the company’s formulation experts.
Metrics analytical chemists work within a current Good Manufacturing Practices-complaint facility on a wide range of oral dosage forms, including potent, cytotoxic, light-sensitive, temperature-sensitive, DEA-regulated, and other challenging molecules.
Metrics Inc. is a full-service pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for oral dosage forms. Our company’s areas of expertise include quality pharmaceutical formulation development; first-time-in-man formulations; Phase I-III clinical trial materials manufacturing; and analytical method development and validation services leading to commercial-scale manufacturing. Our technical capabilities include highly potent, cytotoxic, and unstable compounds; Schedule II-V controlled substances; and products with poor bioequivalence, for which we offer an impressive proprietary portfolio of advanced delivery methods. For more information, visit www.metricsinc.com.
Total Page Views: 646
